Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aardvark Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Aardvark Therapeutics, Inc.

AARD

Aardvark Therapeutics, Inc.

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies targeting gut-based receptors, specifically TAS2Rs, to treat metabolic diseases like hyperphagia and obesity. Its lead candidate, ARD-101, aims to regulate hunger via gut-brain signaling, with potential applications for rare disorders such as Prader-Willi Syndrome and hypothalamic obesity. The company focuses on innovative, gut-restricted compounds to improve efficacy and safety in metabolic health management.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aardvark Therapeutics, Inc.

1
1
Aardvark Therapeutics, Inc. Aardvark Therapeutics Reports Increased Operating Expenses and Net Losses in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Aardvark Therapeutics, Inc. Aardvark Therapeutics Reports $57.6 Million Net Loss and Pauses Clinical Trials

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Aardvark Therapeutics, Inc. Aardvark Therapeutics Reports $16.3 Million Net Loss for Third Quarter 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aardvark Therapeutics, Inc. Aardvark Therapeutics Reports $14.4 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aardvark Therapeutics, Inc. Aardvark Therapeutics Reports $9.3 Million Net Loss and IPO Proceeds of $87.5 Million

Via official filing (AI summary) | about 1 year ago | 0 comments